Endocrinology · 1982
Recombinant Human Insulin (Humulin) Approval
Before October 1982, every vial of insulin in clinical use had been extracted from the ground-up pancreases of slaughterhouse cattle and pigs. The supply chain ran through the meatpacking industry, and the proteins it yielded differed from human insulin by one or three amino acids. For most patients the difference was clinically irrelevant, but for a measurable minority it caused immune reactions: lipodystrophy at injection sites, insulin resistance driven by anti-insulin antibodies, and occasionally systemic hypersensitivity. Demand was also growing faster than bovine and porcine supply could comfortably meet.
The solution came from a collaboration between Genentech and Eli Lilly. In 1979, David Goeddel led the Genentech team in synthesizing the separate genes for the A and B chains of human insulin and expressing them in Escherichia coli, then combining the chains chemically to produce functional insulin identical in sequence to the human pancreatic product. The work was published in the Proceedings of the National Academy of Sciences in 1979. Herbert Boyer, who had co-founded Genentech after pioneering recombinant DNA techniques with Stanley Cohen in the early 1970s, provided the foundational platform that made bacterial protein expression feasible at all. Lilly licensed the technology, scaled fermentation, and submitted to the FDA.
On October 29, 1982, the FDA approved Humulin, the brand name Lilly assigned to the recombinant product. It was the first therapeutic protein manufactured through genetic engineering to reach the commercial market anywhere in the world. Regulatory reviewers had no prior template for evaluating a biologic produced by an engineered organism at industrial scale; the agency had to build its assessment framework from scratch, examining fermentation consistency, purification, immunogenicity, and equivalence to existing insulins.
The clinical transition was deliberate rather than dramatic. Physicians were initially cautious about switching stable patients from animal insulin, and some patients on purified porcine insulin reported that the human-sequence product blunted their hypoglycemia warning symptoms. Over the following decade, however, recombinant insulin progressively displaced animal sources. By the early 2000s, animal-derived insulin had largely disappeared from formularies in high-income countries.
The regulatory and manufacturing pathway Humulin established became the working template for every subsequent biologic approval. Characterization of the recombinant protein, demonstration of safety and efficacy equivalence, and large-scale fermentation quality control requirements were each codified through the Humulin review. When erythropoietin, growth hormone, and then monoclonal antibodies arrived for review, the FDA and EMA adapted that framework rather than building anew. By the 1990s, a generation of drugs that could not exist without recombinant expression technology had entered clinical practice.
Key People
- David Goeddel — Genentech scientist who led the original gene synthesis and bacterial expression
- Herbert Boyer — Genentech co-founder whose recombinant DNA platform underpinned the project
- Stanley Cohen — Stanford biologist who co-developed foundational recombinant DNA cloning techniques with Boyer
- Eli Lilly — Pharmaceutical company that licensed Genentech's technology and scaled manufacturing
Goeddel DV, et al. Proc Natl Acad Sci USA. 1979;76(1):106-110
Related landmarks
- 1971 · Schally and Guillemin: Hypothalamic Releasing Hormones (Endocrinology)
- 1993 · DCCT (Diabetes Control and Complications Trial) (Endocrinology)
- 1994 · Discovery of Leptin (Endocrinology)
- 1998 · UK Prospective Diabetes Study (UKPDS 33) (Endocrinology)